Introduction
============

The composite score JADAS^1,\ 2^ 27-CRP (J27), 10-CRP (J10), and cut-off values for inactive (ID), low (LDA), moderate (MDA) and high disease activity (HDA) were designed to monitor the level of disease activity in all JIA subtypes^1^. The efficacy of canakinumab (CAN), a selective, human, anti-IL-1β monoclonal antibody, was previously demonstrated in SJIA in phase III trials using aACR-JIA response criteria^3^.

Objectives
==========

To assess the level of disease activity in CAN-treated SJIA patients, using J10 and J27 in a 12-week pooled (phase III studies) data set.

Methods
=======

Patients, 2--19 years of age, with active SJIA were enrolled and received sc CAN 4 mg/kg. This post-hoc analysis focuses on a 12-week pooled dataset (from 3 phase III studies) in a total of 178 CAN-naïve patients, assessing the J10 and J27 scores at Days (D) 15, 29, 57, 85, and applies the appropriate cut-off values for ID, LDA, MDA and HDA.

Results
=======

At baseline, the median \[Q1,Q3\] J10 for completer patients (i.e. patients who complete 12 weeks treatment) was 29.1 \[23.1,33.2\], and the median change \[Q1,Q3\] from baseline at D15 and D85 was -19.4 \[-25.7,-13.4\] and -21.2 \[-27.7,-16.7\], respectively. Results for J27 were very similar. The disease status at all time points for J10 and J27 are reported in Table [1](#T1){ref-type="table"}. Median change from baseline at each time point was consistent between the completers and the full analysis dataset for J10 and J27.

###### 

J10 and J27-related disease criteria on all patients

  -----------------------------------------------------------------------
  \%        Disease State\*   Baseline\   D15\    D29\    D57\    D85\
                              N=178       N=172   N=157   N=131   N=125
  --------- ----------------- ----------- ------- ------- ------- -------
  **J10**   ID                0.0         18.0    26.8    34.4    33.6

                                                                  

            LDA               0.0         14.0    11.5    16.8    24.8

                                                                  

            MDA               0.6         19.2    19.7    20.6    16.8

                                                                  

            HDA               99.4        48.8    42.0    28.2    24.8

                                                                  

  **J27**   ID                0.0         18.0    26.8    34.4    33.6

                                                                  

            LDA               0.0         14.0    11.5    16.8    25.6

                                                                  

            MDA               0.6         15.1    16.6    17.6    12.8

                                                                  

            HDA               99.4        52.9    45.2    31.3    28.0
  -----------------------------------------------------------------------

\*Cut-off values for ID, LDA, MDA and HDA, respectively for J10: ≤1, \>1-≤3.8, \>3.8 - ≤10.5, \>10.5; and for J27: ≤1, \>1 - ≤3.8, \>3.8 - ≤8.5, \>8.5

Conclusion
==========

In the pooled 12-week dataset, there was a dramatic reduction in disease activity from baseline to D85, with much of the reduction taking place by D15 onwards in both completers and in the full analysis set. An increasing proportion of CAN patients achieved ID or LDA - according to J10 and J27 - in the first 12 weeks of treatment, despite corticosteroid tapering, a finding consistent with that using the previous ID definition from the phase III trials. These data confirm the early onset of effect as well as the short-term and sustained efficacy over 12 weeks of canakinumab, and suggest that JADAS may represent a useful tool to monitor treatment response.
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